Helsinki-based CurifyLabs, a HealthTech company, has raised €6.7 million to moderniwe and automate the manufacturing of compounded medications, aiming to make them safer and better suited for the specific, individual needs of patients.
The funding round was led by Springvest, a Finland-based growth funding initiative with private investors, and includes a €1 million DeepTech loan from Business Finland. The funding will be used to scale CurifyLabs’ operations and secure high-volume customers in the market.
“The current approach to manufacturing compounded medications is outdated and poorly optimised – failing both pharmacies and the patients they serve. Even with highly trained pharmacists and modern equipment, the process remains unnecessarily labor-intensive, prone to human error, and inconsistent in quality. This can mean that patients with serious conditions may not receive accurate dosages tailored to critical factors like age, weight, and disease severity.
“The consequences are real: a 9-month-old baby with cancer, for example, cannot swallow standard tablets and requires a carefully customised formulation. It’s time to work together and modernise how we deliver personalised medicine – because every patient deserves treatment that truly fits their needs,” says Charlotta Topelius, CEO and Co-founder of CurifyLabs.
Founded in 2021, CurifyLabs has raised a total of €17.6 million and has local offices in Finland, the United States, and Germany. The team boasts several decades of experience in the pharmaceutical and compounding industries. CTO and Co-founder Niklas Sandler is a Professor in Pharmaceutical Technology at Åbo Akademi University in Finland.
According to CurifyLabs, custom-prepared drugs, also known as compounded medications, are critical when commercially available options are not suitable for the individual patient due to dosage requirements, potential allergies, dosage form limitations or drug shortages. Driven by aging populations, chronic diseases, supply chain disruptions, patient demand, and other factors, the global compounding market, currently worth €15 billion, is growing (5.5% CAGR).
Traditionally, when a patient needs personalised medicine, a doctor writes a prescription and then a pharmacist creates the medication by measuring and mixing the ingredients manually.
CurifyLabs says this process is slow, costly and crucial for vulnerable patient populations, such as children and cancer patients. In fact, 50% of medicines are not available in doses or formulations approved for children. Just 1% of drugs are personalised through compounding, despite increasing demand.
“CurifyLabs addresses critical inefficiencies in pharmaceutical compounding while significantly improving medication safety and efficacy for vulnerable patients, like children. We’re seeing rapid growth of the global compounding market which presents an exceptional opportunity for new solutions that have the potential to be ten times better than the existing ways to solve the same challenges,” says Aki Soudunsaari, CEO of Springvest Plc.
CurifyLabs has developed a solution to automate the manufacturing of compounded medicine, reportedly making the process four times faster and enabling limitless dosing flexibility. The Compounding System Solution combines carrier agents and active ingredients, as well as hardware and software, and quality control to automate the manufacturing process of tailored medicines.
In the process, CurifyLabs’ excipient bases, inactive carrier agents, are mixed with active pharmaceutical ingredients from raw materials or crushed tablets. The combination is then dispensed in the desired dosage form, like tablets or liquid, by the Pharma Printer, a desktop-sized compounding robot. An integrated, cloud-based formulation library guides the pharmacist through a validated compounding process, and quality control tools ensure mass uniformity and remove the risk of human errors.
“Simultaneously, CurifyLabs’ entry into the U.S. market, where the vast majority of compounding manufacturing occurs, positions CurifyLabs for substantial growth,” Soudunsaari continues. “We’re delighted to partner with them and we’re confident that the company’s decisive growth steps and innovative approach will make a meaningful difference in people’s everyday lives, globally.”
In addition to the funding round, CurifyLabs has announced the launch of RoboPharma, a €5.6 million EU-funded initiative aiming to create an AI and robotics-driven, decentralised pharmaceutical manufacturing platform. It aims to enhance crisis preparedness across Europe by enabling high-precision production of essential medicines at the point of care. CurifyLabs is set to lead the initiative, which includes six partners across Europe.
Funded through the EU4Health programme, the project addresses one of the most pressing challenges in European healthcare: the fragility and inflexibility of centralised pharmaceutical supply chains during crises such as pandemics, natural disasters, and global disruptions. The mission is to develop and deploy a scalable pharmaceutical production platform for hospital and community pharmacies.
“We have already started operations in the U.S. and are aiming to grow quickly through securing high-volume customers. Automated manufacturing of personalised medicine will provide better medication safety for patients and help pharmacies lower operating costs. We are going to see a major paradigm shift in the manufacturing of personalised medicine, driven by aging populations, chronic diseases, supply chain disruptions, patient demand, and other factors,” concludes Topelius.
Read the orginal article: https://www.eu-startups.com/2025/05/finnish-healthtech-startup-curifylabs-raises-e6-7-million-to-make-medicine-safer-and-more-personalised/
